[go: up one dir, main page]

MX2018005088A - Formulaciones de fenilacetato de l-ornitina. - Google Patents

Formulaciones de fenilacetato de l-ornitina.

Info

Publication number
MX2018005088A
MX2018005088A MX2018005088A MX2018005088A MX2018005088A MX 2018005088 A MX2018005088 A MX 2018005088A MX 2018005088 A MX2018005088 A MX 2018005088A MX 2018005088 A MX2018005088 A MX 2018005088A MX 2018005088 A MX2018005088 A MX 2018005088A
Authority
MX
Mexico
Prior art keywords
phenylacetate
patients
oral formulations
formulation
acute
Prior art date
Application number
MX2018005088A
Other languages
English (en)
Other versions
MX389926B (es
Inventor
Wang Laurene
S Grais Linda
Bukofzer Stanley
Original Assignee
Ocera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/133,087 external-priority patent/US20160338982A1/en
Application filed by Ocera Therapeutics Inc filed Critical Ocera Therapeutics Inc
Publication of MX2018005088A publication Critical patent/MX2018005088A/es
Publication of MX389926B publication Critical patent/MX389926B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Algunas modalidades de la presente solicitud se refieren a formulaciones orales de fenilacetato de L-ornitina y métodos para usar las mismas. Estas formulaciones orales ofrecen ruta alternativa de administración que la administración intravenosa estándar de fenilacetato de Lornitina para tratar hiperamonemia en pacientes que tienen enfermedades y trastornos agudos y crónicos del hígado, por ejemplo, falla hepática aguda, descompensación hepática, hipertensión portal, encefalopatía hepática, o pacientes con trastornos del ciclo de urea.
MX2018005088A 2015-11-13 2016-11-11 Formulaciones de fenilacetato de l-ornitina MX389926B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562255300P 2015-11-13 2015-11-13
US201662276754P 2016-01-08 2016-01-08
US15/133,087 US20160338982A1 (en) 2015-04-20 2016-04-19 Formulations of l-ornithine phenylacetate
PCT/US2016/061678 WO2017083758A1 (en) 2015-11-13 2016-11-11 Formulation of l-ornithine phenylacetate

Publications (2)

Publication Number Publication Date
MX2018005088A true MX2018005088A (es) 2019-05-16
MX389926B MX389926B (es) 2025-03-20

Family

ID=58695607

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018005088A MX389926B (es) 2015-11-13 2016-11-11 Formulaciones de fenilacetato de l-ornitina
MX2022001517A MX2022001517A (es) 2015-11-13 2018-04-25 Formulaciones de fenilacetato de l-ornitina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022001517A MX2022001517A (es) 2015-11-13 2018-04-25 Formulaciones de fenilacetato de l-ornitina.

Country Status (12)

Country Link
EP (1) EP3373923A4 (es)
JP (2) JP7294807B2 (es)
KR (2) KR20250023993A (es)
CN (2) CN113768863A (es)
AU (2) AU2016353350B2 (es)
BR (1) BR112018009349A8 (es)
CA (1) CA3004331A1 (es)
IL (1) IL258630B2 (es)
MX (2) MX389926B (es)
RU (1) RU2018113801A (es)
SG (1) SG11201802987UA (es)
WO (1) WO2017083758A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
US10682325B2 (en) 2017-08-14 2020-06-16 Axcella Health Inc. Compositions and methods for the treatment of liver diseases and disorders associated with one or both of hyperammonemia or muscle wasting
US10596136B2 (en) 2018-06-20 2020-03-24 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
PH12022550738A1 (en) * 2019-10-16 2023-05-08 Mallinckrodt Entpr Llc Dosages and uses of ornithine phenylacetate for treating hyperammonemia
WO2024261477A1 (en) 2023-06-20 2024-12-26 Yaqrit Limited Combination of tlr4 antagonist, ornithine and phenylacetate or phenylbutyrate

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
GB0426141D0 (en) * 2004-11-26 2004-12-29 Ucl Biomedica Plc Treatment
PL1824563T3 (pl) 2004-11-26 2010-07-30 Ucl Business Plc Kompozycje zawierające ornitynę i fenylooctan lub fenylomaślan do leczenia encefalopatii wątrobowej
DE102007009243A1 (de) * 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets
AU2015221466B2 (en) 2009-04-03 2017-02-02 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
SMT201700601T1 (it) * 2009-04-03 2018-03-08 Ocera Therapeutics Inc L-ornitina fenilacetato e metodi per la sua fabbricazione
AU2014250643B2 (en) * 2009-06-08 2016-07-14 Ocera Therapeutics, Inc. Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate
MX2011013129A (es) * 2009-06-08 2012-03-14 Ucl Business Plc Tratamiento de hipertension portal y restauracion de la funcion hepatica usando fenilacetato de l-ornitina.
CN103502203B (zh) * 2010-10-06 2016-09-07 欧塞拉治疗有限公司 制备l-鸟氨酸苯基乙酸盐的方法
CN102993037B (zh) * 2012-11-20 2015-03-04 南京工业大学 一种l-鸟氨酸苯乙酸盐的制备方法
CN103705490B (zh) * 2013-10-31 2016-08-17 蚌埠丰原医药科技发展有限公司 一种门冬氨酸鸟氨酸的缓释制剂及其制备工艺
ES2769000T3 (es) * 2014-11-24 2020-06-24 Ucl Business Ltd Tratamiento de enfermedades asociadas con la activación de células estrelladas hepáticas utilizando terapias reductoras de amoníaco
ES2944311T3 (es) * 2015-04-20 2023-06-20 Ocera Therapeutics Inc Formulaciones de fenilacetato de L-ornitina
AU2016308641B2 (en) * 2015-08-18 2022-02-03 Ocera Therapeutics, Inc. Treatment and prevention of muscle loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate
WO2017053613A1 (en) * 2015-09-25 2017-03-30 Ocera Therapeutics, Inc. Treatment and prevention of neuronal cell loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate

Also Published As

Publication number Publication date
JP2022058446A (ja) 2022-04-12
IL258630B1 (en) 2023-04-01
CA3004331A1 (en) 2017-05-18
JP7294807B2 (ja) 2023-06-20
IL258630B2 (en) 2023-08-01
EP3373923A1 (en) 2018-09-19
MX389926B (es) 2025-03-20
RU2018113801A (ru) 2019-12-16
AU2016353350B2 (en) 2021-09-23
SG11201802987UA (en) 2018-05-30
KR20250023993A (ko) 2025-02-18
WO2017083758A1 (en) 2017-05-18
JP2018533601A (ja) 2018-11-15
IL258630A (en) 2018-06-28
AU2016353350A1 (en) 2018-05-10
KR20180086431A (ko) 2018-07-31
CN113768863A (zh) 2021-12-10
BR112018009349A2 (pt) 2018-11-13
CN108366983A (zh) 2018-08-03
EP3373923A4 (en) 2019-07-03
MX2022001517A (es) 2022-11-16
AU2021290236A1 (en) 2022-02-10
BR112018009349A8 (pt) 2019-02-26

Similar Documents

Publication Publication Date Title
MX2017013170A (es) Formulaciones de fenilacetato de l-ornitina.
CO2019006291A2 (es) Composiciones de aminoácidos y métodos de tratamiento de enfermedades hepáticas
MX2022001517A (es) Formulaciones de fenilacetato de l-ornitina.
CO2019006292A2 (es) Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares
MX2018002990A (es) Uso de la akkermansia pasteurizada para tratar trastornos metabolicos.
CL2019002190A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984)
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
MX2017005236A (es) Profarmacos de carbidopa y l-dopa y metodos de uso.
BR112015017251A2 (pt) composições farmacêuticas compreendendo doadores de nitroxil
BR112019003577A2 (pt) métodos de tratamento da semente e produtos resultantes
PE20160012A1 (es) Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral
MX2016011290A (es) Composiciones de ester de colina de acido lipoico y metodos de uso.
MX2018007871A (es) Composiciones para el cuidado personal.
MX2017000676A (es) Oritavancina de alta pureza y metodo para producir la misma.
BR112016028518A2 (pt) composições farmacêuticas que compreendem dgla e uso do mesmo
MX2017009325A (es) Gel intestinal de levodopa y carbidopa y metodos de uso.
BR112016007238A2 (pt) tienouracilcarboxamidas cíclicas e sua utilização
AR100028A1 (es) Composiciones nutricionales que contienen ácido estearidónico
MX2022004449A (es) Dosis y usos de fenilacetato de ornitina para el tratamiento de hiperamonemia.
BR112017001963A2 (pt) composição farmacêutica oral, seu processo de preparação e método de tratamento
MX2016011025A (es) Composiciones de grapiprant y metodos para usar las mismas.
MX2019000849A (es) Gel intestinal de levodopa y carbidopa y metodos de uso.
MA40645A (fr) Préparation prébiotique à base d'inuline
MX374340B (es) Administracion de farmacos antiinflamatorios no esteroidales y composiciones, metodos y sistemas relacionados.
CY1122377T1 (el) Αργινινη για χρηση στη θεραπεια και/ή προληψη οστεοαρθριτιδας